The company is currently working on six candidates, with a focus on interleukin antibodies. Qyuns has two biosimilar drugs in clinical trials in China, including a biosimilar to tocilizumab, a drug marketed as Actemra for rheumatoid arthritis. Their research and development efforts are aimed at providing clinical products for curing diseases such as asthma and rheumatoid arthritis, with the goal of improving patients' health conditions.